CA
SKYE icon

Clearstead Advisors’s Skye Bioscience SKYE Stock Holding History

Clearstead Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12
Closed -$51 – 3277
2025
Q2 		$51 Buy
+12
New +$25 ﹤0.01% 2668

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clearstead Advisors's SKYE Position: Q3 2025 in Review

Clearstead Advisors sold out of Skye Bioscience (SKYE) in Q3 2025, closing a stake of 12 shares — an estimated $51 sold.

Clearstead Advisors first reported a position in SKYE in Q2 2025 and held it in 1 quarter. The position peaked at $51 in Q2 2025. 58 funds tracked by Wall St. Rank hold SKYE as of Q3 2025.

  • Clearstead Advisors reported no remaining Skye Bioscience position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 12 Skye Bioscience shares in Q3 2025, an estimated $51.
  • Clearstead Advisors first reported a position in Skye Bioscience in Q2 2025 and held it in 1 quarter.
  • Clearstead Advisors's Skye Bioscience position peaked at $51 in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.